A number of research firms have changed their ratings and price targets for Septerna (NASDAQ: SEPN):
- 11/14/2026 – Septerna was downgraded by Wall Street Zen from “hold” to “sell”.
- 11/10/2026 – Septerna had its price target raised by Stifel Nicolaus from $49.00 to $60.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Septerna had its price target raised by Guggenheim from $51.00 to $65.00. They now have a “buy” rating on the stock.
- 11/4/2026 – Septerna had its price target raised by Wells Fargo & Company from $50.00 to $61.00. They now have an “overweight” rating on the stock.
- 10/15/2026 – Septerna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Septerna Stock Down 2.5%
Shares of SEPN traded down $1.08 during trading hours on Monday, reaching $41.52. 201,877 shares of the company traded hands, compared to its average volume of 369,995. The company’s fifty day moving average price is $40.46 and its two-hundred day moving average price is $33.12. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -32.19 and a beta of 2.20. Septerna, Inc. has a 12 month low of $21.31 and a 12 month high of $53.34.
Septerna (NASDAQ:SEPN – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The company had revenue of $18.88 million for the quarter, compared to analysts’ expectations of $20.78 million. On average, analysts expect that Septerna, Inc. will post -1.45 EPS for the current year.
Insider Buying and Selling at Septerna
In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total value of $149,640.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $6,517,158.69. This represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel D. Long sold 3,333 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,647,265.96. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 89,153 shares of company stock valued at $4,210,451. 5.80% of the stock is currently owned by corporate insiders.
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Read More
- Five stocks we like better than Septerna
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Septerna Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna Inc and related companies with MarketBeat.com's FREE daily email newsletter.
